Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.86

+1.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (2831)	2/6/2001 10:35:30 PM
From: Biomaven	Read Replies (2) of 52153

Thanks, rkrw - an instructive release, especially when viewed in retrospect. Note the zinger they slipped in at the end: Anticipated changes in the clinical development plan will result in an expected 2002 filing of the Biologics License Application for rhATIII for use in managing heparin resistance during cardiopulmonary bypass surgery. GTC plans to augment the clinical studies with additional patient exposure data. This was the first indication (that I knew of, at least) that the 1999 year-end BLA filing was no more. (I sold at the opening the day of that announcement - it took several days for the market to figure out what it all meant). It would be revealing to know the actual sequence of events with regard to the FDA discussions. I guess we'll never find out. It is also interesting to look at the insider sales (with papa GENZ being the biggest seller). This was the case of the dog that didn't bark in the night - sustained selling through September 27, 1999 that suddenly stopped. It only resumed on November 9, 1999 shortly after this announcement. This was a good example of the lack of insider selling being the true warning signal. biz.yahoo.com Peter P.S. Anyone catch their webcast today?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next